These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36759402)

  • 21. Patient-reported disease impact of systemic lupus erythematosus with active joint symptoms: Results from the systemic lupus erythematosus-update survey.
    Kamen DL; Birt JA; Hadi MA; Gibbons E; Bushnell DM; Yu R; Delbecque LA; Griffing K; Askanase A
    Lupus; 2023 Mar; 32(3):342-351. PubMed ID: 36541633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus.
    Petri M; Fu W; Ranger A; Allaire N; Cullen P; Magder LS; Zhang Y
    BMC Med Genomics; 2019 Jan; 12(1):4. PubMed ID: 30626389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validity and Reliability of Patient Reported Outcomes Measurement Information System Computerized Adaptive Tests in Systemic Lupus Erythematosus.
    Kasturi S; Szymonifka J; Burket JC; Berman JR; Kirou KA; Levine AB; Sammaritano LR; Mandl LA
    J Rheumatol; 2017 Jul; 44(7):1024-1031. PubMed ID: 28412708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatigue have impact on the sexual problems in Chinese females with systemic lupus erythematosus.
    Zhang L; Wu B; Ye J
    BMC Womens Health; 2022 Jun; 22(1):266. PubMed ID: 35768845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility, Validity, and Reliability of the 10-item Patient Reported Outcomes Measurement Information System Global Health Short Form in Outpatients with Systemic Lupus Erythematosus.
    Kasturi S; Szymonifka J; Burket JC; Berman JR; Kirou KA; Levine AB; Sammaritano LR; Mandl LA
    J Rheumatol; 2018 Mar; 45(3):397-404. PubMed ID: 29419473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative data for care of patients with systemic lupus erythematosus in usual clinical settings: a patient Multidimensional Health Assessment Questionnaire and physician estimate of noninflammatory symptoms.
    Askanase AD; Castrejón I; Pincus T
    J Rheumatol; 2011 Jul; 38(7):1309-16. PubMed ID: 21459938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
    Mok CC; Ho LY; Cheung MY; Yu KL; To CH
    Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT.
    Conti F; Perricone C; Reboldi G; Gawlicki M; Bartosiewicz I; Pacucci VA; Massaro L; Miranda F; Truglia S; Alessandri C; Spinelli FR; Teh LS; Ceccarelli F; Valesini G
    Lupus; 2014 Jul; 23(8):743-51. PubMed ID: 24569393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus.
    Leosuthamas P; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
    Int J Rheum Dis; 2023 Apr; 26(4):667-672. PubMed ID: 36802112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reliability of the SF-36 in Japanese patients with systemic lupus erythematosus and its associations with disease activity and damage: a two-consecutive year prospective study.
    Baba S; Katsumata Y; Okamoto Y; Kawaguchi Y; Hanaoka M; Kawasumi H; Yamanaka H
    Lupus; 2018 Mar; 27(3):407-416. PubMed ID: 28795653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance.
    Holloway L; Humphrey L; Heron L; Pilling C; Kitchen H; Højbjerre L; Strandberg-Larsen M; Hansen BB
    Health Qual Life Outcomes; 2014 Jul; 12():116. PubMed ID: 25048687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations between physicians' global assessment of disease activity and patient-reported outcomes in patients with systemic lupus erythematosus: A longitudinal study.
    Louthrenoo W; Kasitanon N; Morand E; Kandane-Rathnayake R
    Lupus; 2021 Sep; 30(10):1586-1595. PubMed ID: 34192957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon-α.
    Mathian A; Mouries-Martin S; Dorgham K; Devilliers H; Barnabei L; Ben Salah E; Cohen-Aubart F; Garrido Castillo L; Haroche J; Hie M; Pineton de Chambrun M; Miyara M; Sterlin D; Pha M; Lê Thi Huong D; Rieux-Laucat F; Rozenberg F; Gorochov G; Amoura Z
    Arthritis Rheumatol; 2019 May; 71(5):756-765. PubMed ID: 30507062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Charlson Comorbidity Index Is Related to Organ Damage in Systemic Lupus Erythematosus: Data from KORean lupus Network (KORNET) Registry.
    Kim SK; Choe JY; Lee SS
    J Rheumatol; 2017 Apr; 44(4):452-458. PubMed ID: 28298561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal study.
    Wahadat MJ; Schonenberg-Meinema D; van Helden-Meeuwsen CG; van Tilburg SJ; Groot N; Schatorjé EJH; Hoppenreijs EPAH; Hissink Muller PCE; Brinkman DMC; Dvorak D; Verkaaik M; van den Berg JM; Bouchalova K; Kamphuis S; Versnel MA
    Rheumatology (Oxford); 2022 Nov; 61(11):4344-4354. PubMed ID: 35143620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity.
    Svenungsson E; Gunnarsson I; Illescas-Bäckelin V; Trysberg E; Jönsen A; Leonard D; Sjöwall C; Pettersson S
    Lupus Sci Med; 2021 May; 8(1):. PubMed ID: 33972457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.
    Petri MA; Martin RS; Scheinberg MA; Furie RA
    Lupus; 2017 Jan; 26(1):27-37. PubMed ID: 27353505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study.
    Niederkorn A; Frühauf J; Schwantzer G; Wutte N; Painsi C; Werner S; Stradner M; Berghold A; Hermann J; Aberer E
    Arch Dermatol Res; 2018 Aug; 310(6):485-493. PubMed ID: 29728857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validity and reliability of the Lupus QoL index in Turkish systemic lupus erythematosus patients.
    Pamuk ON; Onat AM; Donmez S; Mengüs C; Kisacik B
    Lupus; 2015 Jul; 24(8):816-21. PubMed ID: 25542903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients: a retrospective longitudinal analysis.
    Miyachi K; Iwamoto T; Kojima S; Ida T; Suzuki J; Yamamoto T; Mimura N; Sugiyama T; Tanaka S; Furuta S; Ikeda K; Suzuki K; Niewold TB; Nakajima H
    Arthritis Res Ther; 2023 Feb; 25(1):26. PubMed ID: 36803843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.